Background: We previously reported that the NLRP3 inflammasome played an important role in mediating the podocyte injury induced by aldosterone. However, more studies on the role of the NLRP3 inflammasome in the pathogenesis of podocytopathy are still required. The present study was undertaken to study the role of the NLRP3 inflammasome in angiotensin II (Ang II)-induced podocyte injury, as well as the potential mechanisms. Methods: In this study, we used an Ang II infusion model in NLRP3–/– mice. In cultured podocytes, we used siRNA to silence NLRP3; then we treated the podocytes with Ang II. Results: Following Ang II treatment, we found that the NLRP3 inflammasome was significantly activated in line with mitochondrial dysfunction in a dose- and time-dependent manner. Silencing NLRP3 by siRNA transfection ameliorated podocyte apoptosis, attenuated the loss of the podocyte proteins nephrin and podocin, and protected mitochondrial function. Ang II infusion activated the NLRP3 inflammasome, caused albuminuria, and induced podocyte damage, which was all blocked in the NLRP3–/– mice. At the same time, NLRP3 deletion also ameliorated the mitochondrial dysfunction induced by Ang II infusion. However, the deletion of NLRP3 did not affect the Ang II hypertension. Conclusion: Taken together, these results demonstrate an important role of the NLRP3 inflammasome in mediating Ang II-induced podocyte injury and mitochondrial dysfunction, suggesting that the NLRP3 inflammasome might be an effective therapeutic target against podocytopathy.

Keywords:
Angiotensin II, Mitochondrial dysfunction, NLRP3 inflammasome, Podocyte
1.
Li XC, Zhang J, Zhuo JL: The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res 2017; 125(pt A): 21–38.
2.
Horita S, Nakamura M, Shirai A, Yamazaki O, Satoh N, Suzuki M, Seki G: Regulatory roles of nitric oxide and angiotensin II on renal tubular transport. World J Nephrol 2014; 3: 295–301.
3.
Yang Y, Yang Q, Yang J, Ma Y, Ding G: Angiotensin II induces cholesterol accumulation and injury in podocytes. Sci Rep 2017; 7: 10672.
4.
Rizzo P, Novelli R, Rota C, Gagliardini E, Ruggiero B, Rottoli D, Benigni A, Remuzzi G: The role of angiotensin II in parietal epithelial cell proliferation and crescent formation in glomerular diseases. Am J Pathol 2017; 187: 2441–2450.
5.
Xu Z, Li W, Han J, Zou C, Huang W, Yu W, Shan X, Lum H, Li X, Liang G: Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). Sci Rep 2017; 7: 44911.
6.
Sharma R, Kinsey GR: Regulatory T cells in acute and chronic kidney diseases. Am J Physiol Renal Physiol 2017, Epub ahead of print.
7.
Lee SB, Kalluri R: Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 2010; 119:S22–S26.
8.
Meng XM, Nikolic-Paterson DJ, Lan HY: Inflammatory processes in renal fibrosis. Nat Rev Nephrol 2014; 10: 493–503.
9.
Lv LL, Liu BC: Role of non-classical renin- angiotensin system axis in renal fibrosis. Front Physiol 2015; 6: 117.
10.
Tschopp J, Schroder K: NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010; 10: 210–215.
11.
Patel S: Inflammasomes, the cardinal pathology mediators are activated by pathogens, allergens and mutagens: a critical review with focus on NLRP3. Biomed Pharmacother 2017; 92: 819–825.
12.
Zhuang Y, Ding G, Zhao M, Bai M, Yang L, Ni J, Wang R, Jia Z, Huang S, Zhang A: NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function. J Biol Chem 2014; 289: 25101–25111.
13.
Bai M, Chen Y, Zhao M, Zhang Y, He JC, Huang S, Jia Z, Zhang A: NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. Am J Physiol Renal Physiol 2017; 312:F556–F564.
14.
Liu D, Xu M, Ding LH, Lv LL, Liu H, Ma KL, Zhang AH, Crowley SD, Liu BC: Activation of the Nlrp3 inflammasome by mitochondrial reactive oxygen species: a novel mechanism of albumin-induced tubulointerstitial inflammation. Int J Biochem Cell Biol 2014; 57: 7–19.
15.
Fu R, Guo C, Wang S, Huang Y, Jin O, Hu H, Chen J, Xu B, Zhou M, Zhao J, Sung SJ, Wang H, Gaskin F, Yang N, Fu SM: Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol 2017; 69: 1636–1646.
16.
Che R, Yuan Y, Huang S, Zhang A: Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol 2014; 306:F367–F378.
17.
Yuan Y, Chen Y, Zhang P, Huang S, Zhu C, Ding G, Liu B, Yang T, Zhang A: Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. Free Radic Biol Med 2012; 53: 30–43.
18.
Kadoguchi T, Kinugawa S, Takada S, Fukushima A, Furihata T, Homma T, Masaki Y, Mizushima W, Nishikawa M, Takahashi M, Yokota T, Matsushima S, Okita K, Tsutsui H: Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. Exp Physiol 2015; 100: 312–322.
19.
Mundel P, Reiser J, Kriz W: Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997; 8: 697–705.
20.
Acton BM, Jurisicova A, Jurisica I, Casper RF: Alterations in mitochondrial membrane potential during preimplantation stages of mouse and human embryo development. Mol Hum Reprod 2004; 10: 23–32.
21.
Greka A, Mundel P: Cell biology and pathology of podocytes. Annu Rev Physiol 2012; 74: 299–323.
22.
Urushihara M, Kagami S: Role of the intra-renal renin-angiotensin system in the progression of renal disease. Pediatr Nephrol 2017; 32: 1471–1479.
23.
Della Penna SL, Rosón MI, Toblli JE, Fernández BE: Role of angiotensin II and oxidative stress in renal inflammation by hypernatremia: benefits of atrial natriuretic peptide, losartan, and tempol. Free Radic Res 2015; 49: 383–396.
24.
Chang A, Ko K, Clark MR: The emerging role of the inflammasome in kidney diseases. Curr Opin Nephrol Hypertens 2014; 23: 204–210.
25.
Lorenz G, Darisipudi MN, Anders HJ: Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 2014; 29: 41–48.
26.
Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA: The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010; 21: 1732–1744.
27.
Gong W, Mao S, Yu J, Song J, Jia Z, Huang S, Zhang A: NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy. Am J Physiol Renal Physiol 2016; 310:F1081–F1088.
28.
Wen Y, Liu Y, Tang T, Lv L, Liu H, Ma K, Liu B: NLRP3 inflammasome activation is involved in Ang II-induced kidney damage via mitochondrial dysfunction. Oncotarget 2016; 7: 54290–54302.
29.
Zhang GX, Lu XM, Kimura S, Nishiyama A: Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc Res 2007; 76: 204–212.
30.
Herrera M, Silva GB, Garvin JL: Angiotensin II stimulates thick ascending limb superoxide production via protein kinase Cα-dependent NADPH oxidase activation. J Biol Chem 2010; 285: 21323–21328.
31.
Tsai IC, Pan ZC, Cheng HP, Liu CH, Lin BT, Jiang MJ: Reactive oxygen species derived from NADPH oxidase 1 and mitochondria mediate angiotensin II-induced smooth muscle cell senescence. J Mol Cell Cardiol 2016; 98: 18–27.
32.
Zhuang Y, Yasinta M, Hu C, Zhao M, Ding G, Bai M, Yang L, Ni J, Wang R, Jia Z, Huang S, Zhang A: Mitochondrial dysfunction confers albumin-induced NLRP3 inflammasome activation and renal tubular injury. Am J Physiol Renal Physiol 2015; 308:F857–F866.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.